"Pharmacogenetics of Cancer" - Special Issue

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582607

Authors

Enrico Mini

Stefania Nobili

Affiliations

Soon will be listed here.

Citing Articles

Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma.

Perrone G, Rigacci L, Urru S, Kovalchuk S, Brugia M, Fabbri A Cancers (Basel). 2023; 15(10).

PMID: 37345090 PMC: 10216814. DOI: 10.3390/cancers15102753.

References

Mini E, Nobili S . Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab. 2012; 6(1):17-24. PMC: 2781211. View

Abaji R, Krajinovic M . Pharmacogenetics of asparaginase in acute lymphoblastic leukemia. Cancer Drug Resist. 2022; 2(2):242-255. PMC: 8992626. DOI: 10.20517/cdr.2018.24. View

Alonso-Pena M, Sanchez-Martin A, Sanchon-Sanchez P, Soto-Muniz M, Espinosa-Escudero R, Marin J . Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma. Cancer Drug Resist. 2022; 2(3):680-709. PMC: 8992513. DOI: 10.20517/cdr.2019.006. View

Hierro C, Matos I, Martin-Liberal J, Ochoa de Olza M, Garralda E . Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?. Clin Cancer Res. 2019; 25(11):3210-3219. DOI: 10.1158/1078-0432.CCR-18-3694. View

Belizario J, Loggulo A . Insights into breast cancer phenotying through molecular omics approaches and therapy response. Cancer Drug Resist. 2022; 2(3):527-538. PMC: 8992536. DOI: 10.20517/cdr.2018.009. View

Roden D, McLeod H, Relling M, Williams M, Mensah G, Peterson J . Pharmacogenomics. Lancet. 2019; 394(10197):521-532. PMC: 6707519. DOI: 10.1016/S0140-6736(19)31276-0. View

Wake D, Ilbawi N, Dunnenberger H, Hulick P . Pharmacogenomics: Prescribing Precisely. Med Clin North Am. 2019; 103(6):977-990. DOI: 10.1016/j.mcna.2019.07.002. View

Crisafulli C, Romeo P, Calabro M, Epasto L, Alberti S . Pharmacogenetic and pharmacogenomic discovery strategies. Cancer Drug Resist. 2022; 2(2):225-241. PMC: 8992635. DOI: 10.20517/cdr.2018.008. View

Holohan C, Van Schaeybroeck S, Longley D, Johnston P . Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13(10):714-26. DOI: 10.1038/nrc3599. View

10.

Ravegnini G, Hrelia P, Angelini S . Somatic pharmacogenomics of gastrointestinal stromal tumor. Cancer Drug Resist. 2022; 2(1):107-115. PMC: 9019173. DOI: 10.20517/cdr.2019.02. View

11.

Renfro L, An M, Mandrekar S . Precision oncology: A new era of cancer clinical trials. Cancer Lett. 2016; 387:121-126. PMC: 5023449. DOI: 10.1016/j.canlet.2016.03.015. View

12.

De Mattia E, Roncato R, Dalle Fratte C, Ecca F, Toffoli G, Cecchin E . The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines. Cancer Drug Resist. 2022; 2(1):116-130. PMC: 9019179. DOI: 10.20517/cdr.2019.04. View

13.

Shek D, Read S, Ahlenstiel G, Piatkov I . Pharmacogenetics of anticancer monoclonal antibodies. Cancer Drug Resist. 2022; 2(1):69-81. PMC: 9019180. DOI: 10.20517/cdr.2018.20. View

14.

Franca R, Zudeh G, Pagarin S, Rabusin M, Lucafo M, Stocco G . Pharmacogenetics of thiopurines. Cancer Drug Resist. 2022; 2(2):256-270. PMC: 8992634. DOI: 10.20517/cdr.2019.004. View

15.

Kaehler M, Cascorbi I . Germline variants in cancer therapy. Cancer Drug Resist. 2022; 2(1):18-30. PMC: 9019177. DOI: 10.20517/cdr.2019.05. View

16.

Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 173(2):371-385.e18. PMC: 6029450. DOI: 10.1016/j.cell.2018.02.060. View

17.

Murthy P, Muggia F . PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resist. 2022; 2(3):665-679. PMC: 8992523. DOI: 10.20517/cdr.2019.002. View

18.

Tarantino P, Trapani D, Morganti S, Ferraro E, Viale G, DAmico P . Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. Cancer Drug Resist. 2022; 2(1):43-52. PMC: 9019172. DOI: 10.20517/cdr.2018.22. View

19.

Olivera G, Sendra L, Herrero M, Berlanga P, Gargallo P, Yanez Y . Pharmacogenetics implementation in the clinics: information and guidelines for germline variants. Cancer Drug Resist. 2022; 2(1):53-68. PMC: 9019171. DOI: 10.20517/cdr.2018.25. View

20.

Levitzki A, Klein S . My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. Proc Natl Acad Sci U S A. 2019; 116(24):11579-11586. PMC: 6575164. DOI: 10.1073/pnas.1816012116. View